Heterocyclic Thrombin Inhibitors. Part 2. Quinoxalinone Derivatives as Novel, Potent Antithrombotic Agents.
Uwe J. Ries(Boehringer Ingelheim (Germany)), Herbert Nar(Boehringer Ingelheim (Germany)), Sandra Handschuh(Boehringer Ingelheim (Germany)), Norbert Hauel(Boehringer Ingelheim (Germany)), Jean Marie Stassen(Boehringer Ingelheim (Germany)), Gerhard Mihm(Boehringer Ingelheim (Germany)), Wolfgang Wienen(Pharmazeutische Fabrik Dr. Reckeweg (Germany)), Henning Priepke(Boehringer Ingelheim (Germany))
Cited by 0
Related Papers
Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0
|Journal of Molecular Biology|1991|487
Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors
|Journal of Medicinal Chemistry|2002|454
Biophysics in drug discovery: impact, challenges and opportunities
|Nature Reviews Drug Discovery|2016|383
The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
|European Journal of Pharmacology|1994|374